Loading the security overview…
Where the tokens are
Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q2 FY262026-06-30 | Q1 FY262026-03-31 | Q4 FY252025-12-31 | Q3 FY252025-09-30 | Q2 FY252025-06-30 | Q1 FY252025-03-31 | Q4 FY242024-12-31 | Q3 FY242024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Research and development | $394.92M | $343.97M | $294.94M | $262.51M | $224.13M | $205.75M | $188.10M | $151.75M |
| Selling, general and administrative | $110.21M | $101.25M | $66.68M | $52.76M | $40.58M | $35.01M | $28.21M | $23.96M |
| Operating expenses | $505.13M | $445.22M | $361.63M | $315.27M | $264.71M | $240.76M | $216.31M | $175.71M |
| Operating income | −$505.13M | −$445.22M | −$361.63M | −$315.27M | −$264.71M | −$240.76M | −$216.31M | −$175.71M |
| EBITDA | −$502.68M | −$442.88M | −$359.29M | −$312.94M | −$262.69M | −$238.80M | −$214.31M | −$173.80M |
| Interest income | $35.58M | $19.51M | $21.29M | $22.08M | $22.40M | $24.92M | $21.23M | $20.41M |
| Interest expense | −$23.78M | −$12.20M | −$11.94M | −$11.43M | −$867.00K | $0 | $0 | — |
| Income before taxes | −$644.37M | −$453.82M | −$364.89M | −$305.21M | −$247.79M | −$213.42M | −$195.32M | −$156.29M |
| Income taxes | $0 | $0 | $0 | — | $0 | $0 | −$753.00K | — |
| Net income | −$644.37M | −$453.82M | −$364.89M | −$305.21M | −$247.79M | −$213.42M | −$194.57M | −$156.29M |
| EPS, basic | −$3.06 | −$2.29 | −$1.88 | −$1.61 | −$1.31 | −$1.13 | −$1.12 | −$0.94 |
| EPS, diluted | −$3.06 | −$2.29 | −$1.88 | −$1.61 | −$1.31 | −$1.13 | −$1.12 | −$0.94 |
| Diluted shares | 210.89M | 198.10M | 194.56M | 189.23M | 188.58M | 188.15M | 174.24M | 166.84M |
Figures describe Revolution Medicines shares, not any token. As of Aug 5, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.